106 related articles for article (PubMed ID: 35682800)
1. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
Zhang C; Sheng W; Al-Rawe M; Mohiuddin TM; Niebert M; Zeppernick F; Meihold-Heerlein I; Hussain AF
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682800
[TBL] [Abstract][Full Text] [Related]
2. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
[TBL] [Abstract][Full Text] [Related]
3. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
5. Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.
Ho ECH; Qiu R; Miller E; Bilotta MT; FitzGerald D; Antignani A
Biomed Pharmacother; 2023 Jan; 157():114047. PubMed ID: 36459711
[TBL] [Abstract][Full Text] [Related]
6. EGFR as a potent CAR T target in triple negative breast cancer brain metastases.
Subham S; Jeppson JD; Worcester C; Schatmeyer B; Zhao J; Madan R; Lakis NS; Kimler BF; McGuirk JP; Chen RC; Stecklein SR; Akhavan D
Breast Cancer Res Treat; 2023 Jan; 197(1):57-69. PubMed ID: 36318382
[TBL] [Abstract][Full Text] [Related]
7. Applications of SNAP-tag technology in skin cancer therapy.
Padayachee ER; Adeola HA; Van Wyk JC; Nsole Biteghe FA; Chetty S; Khumalo NP; Barth S
Health Sci Rep; 2019 Feb; 2(2):e103. PubMed ID: 30809593
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.
Wang P; Zhou R; Zhou R; Feng S; Zhao L; Li W; Lin J; Rajapakse A; Lee CH; Furnari FB; Burgess AW; Gunter JH; Liu G; Ostrikov KK; Richard DJ; Simpson F; Dai X; Thompson EW
Redox Biol; 2024 Feb; 69():102976. PubMed ID: 38052106
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.
Si Y; Xu Y; Guan J; Chen K; Kim S; Yang ES; Zhou L; Liu XM
Eng Life Sci; 2021 Jan; 21(1-2):37-44. PubMed ID: 33531889
[TBL] [Abstract][Full Text] [Related]
10. EGFR-targeted humanized single chain antibody fragment functionalized silica nanoparticles for precision therapy of cancer.
Wu H; Ding X; Chen Y; Cai Y; Yang Z; Jin J
Int J Biol Macromol; 2023 Dec; 253(Pt 8):127538. PubMed ID: 37866562
[TBL] [Abstract][Full Text] [Related]
11. Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer.
Mirzaei R; Shafiee S; Vafaei R; Salehi M; Jalili N; Nazerian Z; Muhammadnajad A; Yadegari F; Reza Esmailinejad M; Farahmand L
Int Immunopharmacol; 2023 Sep; 122():110656. PubMed ID: 37473710
[TBL] [Abstract][Full Text] [Related]
12. Targeted Drug Delivery by MMAE Farnesyl-Bioconjugated Multivalent Chemically Self-Assembled Nanorings Induces Potent Receptor-Dependent Immunogenic Cell Death.
Wang Y; Kilic O; Rozumalski L; Distefano MD; Wagner CR
Bioconjug Chem; 2024 May; 35(5):582-592. PubMed ID: 38701361
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: from none to multiple therapeutic targets in two decades.
Carvalho FM
Front Oncol; 2023; 13():1244781. PubMed ID: 38023167
[TBL] [Abstract][Full Text] [Related]
14. Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment.
Marshall SK; Panrak Y; Makchuchit N; Jaroenpakdee P; Saelim B; Taweesap M; Pachana V
Bioengineering (Basel); 2022 Jun; 9(7):. PubMed ID: 35877345
[TBL] [Abstract][Full Text] [Related]
15. Development of potent antibody drug conjugates against ICAM1
Zhu B; Wang X; Shimura T; Huang AC; Kong N; Dai Y; Fang J; Guo P; Ying JE
NPJ Precis Oncol; 2023 Sep; 7(1):93. PubMed ID: 37717087
[TBL] [Abstract][Full Text] [Related]
16. Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.
Chia PL; Parakh S; Tsao MS; Pham NA; Gan HK; Cao D; Burvenich IJG; Rigopoulos A; Reilly EB; John T; Scott AM
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33023139
[TBL] [Abstract][Full Text] [Related]
17. In silico investigation of a novel anti-EGFR scFv-IL-24 fusion protein induces apoptosis in malignant cells.
Zaroon ; Yousaf N; Aslam S; Qureshi S; Bashir H
J Mol Model; 2023 Aug; 29(9):282. PubMed ID: 37606822
[TBL] [Abstract][Full Text] [Related]
18. Multi-Color Enhanced Fluorescence Imaging of a Breast Cancer Cell with A Hole-Arrayed Plasmonic Chip.
Yoshida M; Chida H; Kimura F; Yamamura S; Tawa K
Micromachines (Basel); 2020 Jun; 11(6):. PubMed ID: 32580380
[TBL] [Abstract][Full Text] [Related]
19. Targeting of the epidermal growth factor receptor with mesoporphyrin IX-peptide conjugates.
Fontenot KR; Ongarora BG; LeBlanc LE; Zhou Z; Jois SD; Vicente MG
J Porphyr Phthalocyanines; 2016 Jan; 20(1-4):352-366. PubMed ID: 27738394
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum to "Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)" [Cancer Treatment Reviews 123 (2024) 102672].
Dri A; Arpino G; Bianchini G; Curigliano G; Danesi R; De Laurentiis M; Del Mastro L; Fabi A; Generali D; Gennari A; Guarneri V; Santini D; Simoncini E; Zamagni C; Puglisi F
Cancer Treat Rev; 2024 Apr; 125():102714. PubMed ID: 38493647
[No Abstract] [Full Text] [Related]
[Next] [New Search]
